Highly sensitive C-reactive protein levels in Iranian patients with pulmonary complication of sulfur mustard poisoning and its correlation with severity of airway diseases

Abstract

Background: Sulfur mustard (SM) is a chemical warfare agent that can cause serious pulmonary complications. This study was designed to determine serum highly sensitive C-reactive protein (hs-CRP) and evaluate its correlation with lung function parameters in patients with chronic obstructive pulmonary disease (COPD) due to SM poisoning. Methods: Fifty consecutive SM patients with stable COPD and a mean age 46.3 ± 9.18 years were enrolled in this cross sectional study. Thirty healthy men were selected as controls. Lung function parameters were evaluated. Serum hs-CRP by immunoturbidometry assay was measured in both the patients and controls. Results: In the case group, the mean forced expiratory volume in one second (FEV1) was 2.14 ± 0.76 L (58.98% ± 17.51% predicted). The mean serum hs-CRP was 9.4 ± 6.78 SD and 3.9 ± 1.92 SD mg/L in the cases and controls, respectively, with significant statistical differences (p < .001). There was negative correlation between the serum hs-CRP and FEV1 levels (p = .01). The serum hs-CRP levels were also correlated with Global Initiative for Chronic Obstructive Lung disease (GOLD) stages (r = .45, p < .001). Conclusions: Our findings suggest that the serum hs-CRP level is increased in SM patients with COPD and may have a direct correlation with disease severity. It may then be used as a marker for the severity of COPD in patients with SM poisoning.

Keywords

chemical warfare agents sulfur mustard gas veterans chronic obstructive pulmonary disease highly sensitive C-reactive protein

References

Balali- Mood M. , Hefazi M. Comparison of early and late toxic effects of sulfur mustard in Iranian veterans. Basic Clin Pharmacol Toxicol 2006; 99: 273-282.

Ghanei M. , Adibi I. Clinical review of mustard lung. IJMS 2007 ; 32: 58-65.

Ghanei M. , Amiri S. , Akbari H. , et al. Correlation of sulfur mustard exposure and tobacco use with expression (immunoreactivity) of p53 protein in bronchial epithelium of Iranian ‘‘mustard lung’’ patients. Mil Med 2007; 172: 70-74.

Balali-Mood M. , Hefazi M. , Mahmoudi M. , et al. Long-term complications of sulfur mustard poisoning in severely intoxicated Iranian veterans. Fundam Clin Pharmacol 2005; 19: 713-721.

Khateri S. , Ghanei M. , Keshavarz S. , Soroush M. , Hainez D. Incidence of lung, eye, and skin lesions as late complications in 34,000 Iranians with wartime exposure to mustard agent. J Occup Environ Med 2003; 45: 1136-1143.

Ghanei M. , Khalili AR , Arab MJ , et al. Diagnostic and therapeutic value of short term corticosteroid therapy in exacerbation of mustard gas induced chronic bronchitis. Basic Clin Pharmacol Toxicol 2005; 97: 302-305.

deTorres JP , Cordoba-Lanus E. , Lopez-Aguilar C. , et al. C-reactive protein levels important predictive outcomes in stable COPD patients. Eur Respir J 2006; 27: 902-907.

Pinto-Plata VM , Mullerova H. , Toso JF , Feudjo-Tepie M. , Soriano JB , Vessey RS C-reactive protein in patients with COPD, control smokers, and nonsmokers. Thorax 2006 ; 61: 23-28.

Ridker PM Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003 ; 107: 363-369.

10.

Mannino DM , Ford ES , Redd SC Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition. Examination. Am J Med 2003; 114: 758-762.

11.

Wouters EFM The systemic face of airway diseases: the role of C-reactive protein. Eur Respir J 2006 ; 27: 877-879.

12.

Dahl M. , Vestibo J. , Lange P. , Bojesen SE , Tybjærg A. , Nordestgaard BG C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 250-255.

13.

Gan WQ , Man SF , Sin DD The interactions between cigarette smoking and reduced lung function on systemic inflammation. Chest 2005; 127: 558-564.

14.

Gan WQ , Man SF , Senthilselvan A. , Sin DD Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and meta analysis. Thorax 2004; 59: 574-580.

15.

Malo O. , Sauleda J. , Busquets X. , Miralles C. , Agusti AG , Noguera A. Systemic inflammation during exacerbations of chronic obstructive pulmonary disease. Arch Broncopneumol 2002 ; 38: 172-176.

16.

Sin DD , Man SF Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular disease? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107: 1514-1519.

17.

American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 52: S77-S121.

18.

Jones PW , Spencer S. , Adie S. The St George Respiratory Questionnaire Manual. London : Respiratory Medicine, 2003.

19.

Pauwels RA , Buist AS , Caleverleg PM , Jenkins CR , Hurd SS Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global initiative for obstructive lung disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-1276.

20.

Celli BR , Cote CG , Marin JM , et al. The body mass index, airflow obstruction, dyspnea and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 1005-1012.

21.

American Thoracic Society. ATS statement: Guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: 111-129.

22.

Ghanei M. , Tazelaar HD , Chilosi M. , et al. An international collaborative pathologic study of surgical lung biopsies from mustard gas-exposed patients. Respiratory Medicine 2008; 102: 825-830.

23.

Broekhuizen R. , Wouters EF , Creutzberg EC , Schols AM Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 2006; 61: 17-22.

24.

Teramoto S. , Kume H. , Ishii T. , et al. Reference values for 6-min walk distance in Asian adults may not be different from that of Caucasian adults. Respirology 2006; 11: 669-670.

25.

Attaran D. , Khajedaloui M. , Jafarzadeh R. , Mazloomi M. Health related quality of life in patients with chemical warfare induced COPD . Arch of Iranian Medicine 2006; 9: 359-363.

26.

Ridker PM , Libby P. Risk factors for atherothrombotic disease. In: Libby P , Bonow RO , Mann DL , Zipes DP (eds.) Braunwald’s heart diseases: a textbook of cardiovascular medicine. St Louis: Saunders, 2008, p.1014.